Xilio Therapeutics, Inc.
XLO
$0.709
$0.04757.18%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 6.61% | -0.68% | 19.05% | 2.56% | -5.42% |
| Total Depreciation and Amortization | -1.57% | -14.38% | 0.45% | -1.34% | -2.39% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -3.68% | 4.30% | -17.52% | -5.86% | 3.24% |
| Change in Net Operating Assets | -83.78% | -105.04% | 621.24% | 141.46% | 77.27% |
| Cash from Operations | -3.55% | -168.52% | 289.99% | 21.78% | -0.43% |
| Capital Expenditure | 33.33% | 57.14% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 33.33% | 57.14% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 66.67% | 99.37% | -98.70% | 24.78% |
| Issuance of Common Stock | 204,950.00% | -99.98% | 365.74% | 7,877.78% | 575.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 273,500.00% | -100.01% | 2,000.94% | 158.38% | 26.92% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 56.44% | -134.23% | 518.67% | 36.60% | 3.49% |
